Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed ľ December 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
DIN-HM
Homeopathic Medicine Number
MECS
Ministerial Executive Correspondence System
NPN
Natural Product Number
For the month of December 2013
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00536 Documents related to an infant formula company with the brand name Life. (Jan 1, 2007 to Jul 28, 2010). Disclosed in part 14
A-2010-01264 All email correspondence about allergen labelling regulations to and from Samuel Godefroy. (Dec 1, 2010 to Feb 7, 2011). Disclosed in part 213
A-2011-00154 Information regarding ENBREL by Immunex Corporation. Disclosed in part 514
A-2011-01406 Information regarding Tasigna by Novartis. Disclosed in part 322
A-2011-01538 Information regarding THRIVE GUM, NPN 80000396 and 80000402. Disclosed in part 254
A-2012-00027 Documents pertaining to viral DNA (Deoxyribonucleic acid) contaminants of the human papilloma virus vaccines in use in Canada, Health Canada's response to any indication of such contamination and viral DNA contamination of other vaccines in use in Canada. Disclosed in part 138
A-2012-00259 All documents related to potential safety risk with respect to the Morcellex Tissue Morcellator. (Jan 1, 1996 to May 7, 2012). Disclosed in part 50
A-2012-00264 All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare Prosima Pelvic Floor Repair System. (Jan 1, 1996 to May 7, 2012). Disclosed in part 42
A-2012-00270 All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare TVT Abbrevo Continence System. (Jan 1, 1996 to May 7, 2012). Disclosed in part 48
A-2012-00273 All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for Gynecare TVT Exact Continence System. (Jan 1, 1996 to May 7, 2012). Disclosed in part 48
A-2012-00514 Information regarding MYLAN-TELMISARTAN HCTZ, DIN 02373564, 02373572 by Mylan Pharmaceuticals ULC and TEVA-TELMISARTAN HCTZ, DIN 02330288, 02379252 by Teva Canada Limited. Disclosed in part 491
A-2012-00559 Agenda, minutes and supporting documents for Health Canada's Healthy People and Communities Steering Committee. (Jan1, 2012 to Jul 1, 2012). Disclosed in part 21
A-2012-00802 Information regarding CLARUS (Isotretinoin) by Mylan Pharmaceuticals ULC. Disclosed in part 49
A-2012-00983 Information regarding PLEGISOL, DIN 00625663 by HOSPIRA HEALTHCARE CORPORATION. Disclosed in part 183
A-2012-01459 AER for Synthroid. Report number: 000425626. Disclosed in part 2
A-2012-01532 AERs for Diane-35. Report numbers: 000159161, 000161353, 000135800, 000159294 and 000157930. Disclosed in part 16
A-2012-01619 AERs for Humulin. Report numbers: 000389327 and 000401731. Disclosed in part 7
A-2012-01620 AERs for Strattera. Report numbers: 000392742, 000381559, 000383616, 000381878, 000400638, 000400816, 000407429, 000414330, 000418812 and 000429938. Disclosed in part 20
A-2013-00020 All documents regarding the Adverse Reaction Reports for Pradex. Disclosed in part 178
A-2013-00110 All comments received in response to the Pest Management Regulatory Agency's public consultation for the Proposed Re-evaluation Decision (PRVD) on Boric Acid and its Salts (Boron) (PRVD2012-03) posted on October 16, 2012. Disclosed in part 877
A-2013-00198 List of problem reports received pertaining to Automated External Defibrillators. (From Jan 1, 2005 to Dec 31, 2006 and from Jan 2, 2012 to May 9, 2013). Disclosed in part 52
A-2013-00345 Information regarding Rubbing Alcohol Compound, NPN 00167630 by RW Packaging Ltd. Disclosed in part 44
A-2013-00419 Documents pertaining to breakfast programs as a preventative measure against child obesity. (Jan 1, 2010 to Dec 9, 2013). Disclosed in part 296
A-2013-00502 Information regarding the medical device Circulation Maxx Ultra, License number 91704 by TV Products HK Ltd. Disclosed in part 30
A-2013-00539 AER for Docetaxel. Report number: 000504984. Disclosed in part 4
A-2013-00587 At the time of the repeal of licences issued under the Marihuana Medical Access Regulations on March 31, 2014, based on the actual applications received by Health Canada, as well as the licences Health Canada anticipates to issue for production of cannabis, the anticipated total annual production capacity of dried cannabis, of all anticipated Licensed Producers under the Marihuana for Medical Purposes Regulations estimated to be as of April 1, 2014. Disclosed in part 8
A-2013-00597 AERs for Lantus. Report numbers: 000473779 and 000475205. Disclosed in part 12
A-2013-00629 Information regarding Suboxone, DIN 02295695, 02295709 by RB Pharmaceuticals Limited. No records exist 0
A-2013-00634 Information regarding Collagen; Cartilagen; Colla-Joint; Collagen 400 Mg; Hydrolagen; Lacogen, NPN 80039378 by Pharmetics (2011) Inc. Disclosed in part 72
A-2013-00660 AER for Eloxatin. Report number: 000511648. Disclosed in part 3
A-2013-00688 AERs for Avelox. Report numbers: 000504411, 000503656, 000499943, 000497113 and 000497676. Disclosed in part 8
A-2013-00711 The number licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within the city of Abbotsford, British Columbia All disclosed 1
A-2013-00733 AERs for the following products/report numbers: Perindopril (000446835), Coversyl Plus (000435816, 000443532), Diamicron (000415106), Indapamide (000380218). Disclosed in part 31
A-2013-00736 All briefing notes/memos prepared for the Minister and the Minister's office relating to prescription heroin (or otherwise known as diacetylmorphine). (Jun 1, 2013 to Sep 23, 2013). No records exist 0
A-2013-00737 All documents regarding the Adverse Reaction for birth control pills. (Jan 1, 2009 to Sep 26, 2013). All disclosed 1,198
A-2013-00739 List of all drugs released through the Special Access Programme. (Jan 1, 2012 to Sep 26, 2013). All disclosed 11
A-2013-00756 Briefing notes, internal reports, Health Canada press releases and studies in regards to elderly suicide. (Jan 1, 2011 to Aug 31, 2013). All disclosed 8
A-2013-00762 All documents in MECS for the following file: 13-107202-553, subject: Ring of Fire. All disclosed 16
A-2013-00764 All documents in MECS for the following file: 13-107016-47. Subject: Chemicals Management Plan Timelines 2013-2016. Disclosed in part 28
A-2013-00770 AERs: 000455368, 000463398, 000451972, 000451975, 000452321, 000463332 and 000490008. Disclosed in part 20
A-2013-00771 Documents submitted by Prairie Plant Systems to Health Canada regarding their successful application for Marihuana for Medical Purposes Regulations. Disclosed in part 67
A-2013-00773 The total number of valid licenses to produce Cannabis (marihuana) that have been issued by Health Canada under the Marihuana Medical Access Program to recipients within the City of Surrey, British Columbia. (Oct 31, 2011 to Aug 1, 2013). All disclosed 1
A-2013-00788 Information regarding Hydrolyzed Collagen, NPN 80045110 by Canadian Phytopharmaceuticals Corporation. Disclosed in part 28
A-2013-00789 Documents created or received by the deputy minister of health and/or staff, related to meetings between the Health Canada and representatives of Under Pressure Inc., a hyperbaric medicine clinic, including its co-owners. (Jan 1, 2008 to Dec 31, 2010). No records exist 0
A-2013-00823 Information regarding Nutri King Salmon Collagen 200 Mg, NPN 80044725 by Canvors Corporation Canada Ltd. Disclosed in part 53
A-2013-00825 List of each individual and corporation that has submitted an application to become a licensed producer under the new Marihuana for Medical Purposes Regulations. Disclosed in part 10
A-2013-00857 Information regarding Oscillococcinum; Oscillo, DIN-HM 80014156. Disclosed in part 16
A-2013-00867 Information regarding how Health Canadaĺs, Canada Health Act Division fulfills its duty to ensure criteria of the Canada Health Act are met respecting public administration of Medicare. All disclosed 177
A-2013-00871 List of contracts of $10,000 or less in value. (Jan 1, 2013 to Oct. 29, 2013). All disclosed 137
A-2013-00890 Documents related to a historic Kamloops-related health study, Kamloops physicians were required to collect core blood from newborn infants at Royal Inland Hospital for an extended period ending in 1999. No records exist 0
A-2013-00895 All correspondence regarding Steven Fletcher's comments on assisted suicide. (Sep 23, 2013 to Oct 23 2013). All disclosed 28
A-2013-00899 Documents referring to both Libby Davies and heroin. (Sep 18, 2013 to Oct 18, 2013). All disclosed 17
A-2013-00906 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during September 2013. All disclosed 4
A-2013-00916 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Amendments to Rio Tinto Alcan Inc.'s British Columbia P2-00001 Multimedia Permit. No records exist 0
A-2013-00942 AERs for Mirena. Report numbers: 000507215, 000504633, 000508319 and 000510150. Disclosed in part 4
A-2013-00943 AERs for Magnevist. Report numbers: 000507678 and 000505483. Disclosed in part 4
A-2013-00944 AER for Gadovist. Report number: 000511188. Disclosed in part 4
A-2013-00946 AER for Adalat XL. Report number: 000506494. Disclosed in part 5
A-2013-00947 AER for Yasmin. Report number: 000508692. Disclosed in part 2
A-2013-00948 AER for Yaz. Report number: 000508740. Disclosed in part 1
A-2013-00950 A listing of the Access to Information requests submitted to Health Canada. (Oct 1, 2013 to Oct 31, 2013). Disclosed in part 12
A-2013-00961 AER for Biaxin. Report number: 000529184. Disclosed in part 1
A-2013-00962 AER for Epival. Report number: 000515662. Disclosed in part 2
A-2013-00973 AER for Adacel. Report number: 000518541. Disclosed in part 3
A-2013-00974 AER for Ferrlecit. Report number: 000535178. Disclosed in part 1
A-2013-00975 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during October 2013. All disclosed 3
A-2013-00976 AER for Ferrlecit. Report number: 000531665. Disclosed in part 1
A-2013-00977 AER for Adacel. Report number: 000537009. Disclosed in part 1
A-2013-00978 AER for Intanza. Report number: 000518541. Disclosed in part 3
A-2013-00980 AERs. Report numbers: 000520801, 000526131 and 000531183. Disclosed in part 6
A-2013-00991 Electronic file of all employees, their positions and their salary classifications as of November 19, 2013. All disclosed 122
A-2013-01000 Ministerial Agreement/Exemption granted on March 18, 2004 by the federal Minister of Health Pierre Pettigrew to the Synergy Group of Canada Inc. and Truehope Nutritional Support Ltd. allowing these companies to sell Empower Plus dietary supplement. No records exist 0
A-2013-01003 AER. Report number: 000453103. Disclosed in part 1
A-2013-01005 AERs for Midol. Report numbers: 000516753 and 000535428. Disclosed in part 2
A-2013-01006 AER for Aleve. Report number: 000532366. Disclosed in part 1
A-2013-01017 AERs for Xarelto. Report numbers: 000513479, 000514211, 000516075, 000516516, 000516541, 000517023, 000517291, 000517367, and 000520051. Disclosed in part 11
A-2013-01018 AER for Stivarga. Report number: 000518626. Disclosed in part 1
A-2013-01019 AERs for Mirena. Report numbers: 000513419, 000513439, 000515924 and 000517884. Disclosed in part 8
A-2013-01020 AERs for Nexavar. Report numbers: 000517883 and 000520008. Disclosed in part 10
A-2013-01021 AERs for Gadovist. Report numbers: 000514653, 000516265 and 000518176. Disclosed in part 3
A-2013-01022 AERs for Diane-35. Report numbers: 000514350 and 000516118. Disclosed in part 3
A-2013-01023 AERs for Cipro. Report numbers: 000513183, 000513257 and 000517287. Disclosed in part 3
A-2013-01024 AERs for Avelox. Report numbers: 000512430, 000516676 and 000519746. Disclosed in part 6
A-2013-01025 AER for Adalat XL. Report number: 000512159. Disclosed in part 1
A-2013-01039 A list of briefing notes prepared for the minister. (Sep 1, 2013 to Nov 25, 2013). Disclosed in part 45
A-2013-01043 AER for Eloxatin. Report number: 000526575. Disclosed in part 1
A-2013-01045 AER for Eloxatin. Report number: 000526577. Disclosed in part 2
A-2013-01051 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during November 2013. All disclosed 3
A-2013-01052 AER for Eloxatin. Report number: 000531653. Disclosed in part 1
A-2013-01053 AER for Eloxatin. Report number: 000521952. Disclosed in part 1
A-2013-01054 AER for Eloxatin. Report number: 000535311. Disclosed in part 1
A-2013-01055 AER for Eloxatin. Report number: 000532166. Disclosed in part 1
A-2013-01056 AER for Eloxatin. Report number: 000529565. Disclosed in part 1
A-2013-01063 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Impacts of that particular aluminum smelter and potential industrial development in Kitimat on the Kitimat-Terrace airshed. No records exist 0
A-2013-01064 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Cost-benefit analysis of the human health or environmental impacts. Financial costs associated with the installation of scrubber technologies. Potential human health or environmental impacts. No records exist 0
A-2013-01065 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Experience of jurisdictions other than the Province of British Columbia that have or have not required industrial emitters of SO2 to install scrubber technologies. No records exist 0
A-2013-01066 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Historical emission rates, air pollutant dispersion studies, or ambient concentrations of pollutants in the Kitimat-Terrace airshed. No records exist 0
A-2013-01067 All documents regards to the application of Rio Tinto Alcan Inc. to increase SO2 (Sulphur dioxide) emissions from its aluminum smelter in Kitimat, British Columbia: Province of British Columbia's October 3, 2013 announcement of the funding of an airshed study to assess effects of existing and proposed industrial development. No records exist 0